Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery

Y. D. Kim, M. L. Foegh, R. B. Wallace, L. Ng, S. W. Ahmed, N. M. Katz, R. Siegelman, K. Franco, F. Douglas, E. Ku, B. Sen, P. Ramwell

Research output: Contribution to journalArticlepeer-review

Abstract

Pulmonary hypertension with an elevated pulmonary vascular resistance was observed during the immediate recovery period in patients who underwent mitral valve surgery. In eight such patients, intravenous infusion of CGS-13080, imidazo(1,5-a)pyridine-5-hexanoic acid (a thromboxane synthetase inhibitor), at a dose range of 0.08-0.1 mg/kg/hr, effectively reduced pulmonary hypertension (from a mean pulmonary arterial pressure of 36 ± 2 to 31 ± 2 torr) and pulmonary vascular resistance (from 339 ± 38 to 238 ± 37 dynes · sec · cm-5) within 30 minutes and remained reduced for the entire infusion period (48 hours in five patients and 18 hours in three patients). Mean arterial pressure or systemic vascular resistance were not significantly affected by the drug infusion. Serum thromboxane B2 levels (a stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximum effect of greater than 90% reduction. All patients tolerated the drug infusion without significant side effects.

Original languageEnglish (US)
JournalCirculation
Volume78
Issue number3 II SUPPL.
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery'. Together they form a unique fingerprint.

Cite this